Eye Care

Ranibizumab-eqrn is the only biosimilar approved for all 5 Lucentis indications.

Thera Tears helps with the symptoms of dry eyes.

Findings suggest potential screening and disease detection opportunities.

Treatment with faricimab-svoa (Vabysmo) may improve vision with fewer injections and treatment sessions for patients with wet age-related macular degeneration compared to other treatments.

If approved, the 16-week dosing regimen could offer certain individuals a potentially longer treatment interval and physicians with greater flexibility to individualize treatment.

Olopatadine stabilizes ocular mast cells to prevent histamine release by allergens.

Acuvail ophthalmic solution is a nonsteroidal, anti-inflammatory indicated for the treatment of pain and inflammation following cataract surgery.

In clinical trials, Xiidra was found to improve eye dryness scores significantly compared with placebo.

Pilocarpine (Vuity) is a cholinergic muscarinic receptor agonist indicated for the treatment of presbyopia in adults.

PinkEye Relief are sterile eye drops that temporarily relieve burning, swelling, and crusting.

Brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5% is a generic equivalent to AbbVie’s Combigan, which reduces eye pressure in patients with ocular hypertension.

The eye drop treats age-related blurry near vision in adults and is FDA-approved for once-daily administration.

The FDA has approved pilocarpine hydrochloride ophthalmic solution 1.25% (Vuity, Allergan, an AbbVie company) to treat presbyopia in adults.1

FDA approves the EVO/EVO+ Visian Implantable Collamer Lens for the correction of myopia and myopia with astigmatism.

Systane is a lubricating eye drop indicated for dry eye relief.

Dorzolamide/timolol (Cosopt) is indicated for patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers.

The majority of study participants demonstrated improvement of infraorbital hollows through 1 year.

PreserVision is a supplement that may help lower the risk of progression of moderate-to-advanced age-related macular degeneration.

Faricimab-svoa targets and inhibits 2 disease pathways that drive diabetic macular edema and neovascular or “wet” age-related macular degeneration.

Ten quiz questions to assess your knowledge on common symptoms and treatments for glaucoma.

Data from 4 analyses show that individuals treated with the drug achieved non-inferior vision gains compared with aflibercept.

Lifitegrast ophthalmic solution (Xiidra) 5% is indicated for the treatment of the signs and symptoms of dry eye disease.

Cequa ophthalmic solution is indicated to increase tear production in patients with dry eyes.

Brimonidine ophthalmic solution (Alphagan P) is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Combigan is comprised of 2 components that reduce elevated intraocular pressure, whether or not associated with glaucoma.

If glaucoma is recognized early, vision loss can be slowed or prevented.

Besifloxacin ophthalmic suspension (Besivance) is indicated for the treatment of bacterial conjunctivitis.

But gene therapy may be the next big change; researchers recently identified a calcium modulator that protects the optic nerve in mice.

Pharmacists can play a key role in providing education and guidance to patients with glaucoma.

Fuchs' dystrophy causes fluid build up in the cornea, resulting in swelling.